Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

CNBC's Jim Cramer talks about his take on Moderna's stock performance and business outlook.

CNBC's Jim Cramer talks about his take on Moderna's stock performance and business outlook.

Key Points Interested in Moderna, Inc.? Here are five stocks we like better. Moderna shares rose nearly 20% after Science Day ...

At Science Day, Moderna outlined growth plans across infectious-disease vaccines, Intismeran, and rare-disease therapeutics. ...

Moderna stock soars on positive updates during the Science Day presentation. Jefferies sees significant further upside in ...

Provides broad overview of Company's research and early development programs expected to continue to fuel future ...

Moderna (MRNA) stock jumps on Science Day pipeline update and FDA flu vaccine vote; see key catalysts, technical levels, and ...

Moderna just received fantastic news.

The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to ...

Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.

Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to ...